What challenges remain in chronic myeloid leukemia research?
作者信息
Carella Angelo M, Branford Susan, Deininger Michael, Mahon Francois X, Saglio Giuseppe, Eiring Anna, Khorashad Jamshid, O'Hare Thomas, Goldman John M
出版信息
Haematologica. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381.
Abstract
摘要
相似文献
1
What challenges remain in chronic myeloid leukemia research?慢性髓性白血病研究中仍存在哪些挑战？
Haematologica. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381.
2
Chronic myeloid leukemia. Sceptical scientists.慢性髓性白血病。持怀疑态度的科学家。
Lancet. 2001 Dec;358 Suppl:S11. doi: 10.1016/s0140-6736(01)07024-6.
3
Chronic myelogenous leukaemia--new therapeutic principles.慢性粒细胞白血病——新的治疗原则
J Intern Med. 2001 Jul;250(1):3-9. doi: 10.1046/j.1365-2796.2001.00823.x.
4
Imatinib mesylate.甲磺酸伊马替尼
Am J Health Syst Pharm. 2001 Dec 1;58(23):2241-2. doi: 10.1093/ajhp/58.23.2241.
5
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.bcr-abl酪氨酸激酶抑制剂在慢性粒细胞白血病中的现状
Curr Opin Oncol. 2000 Nov;12(6):594-7. doi: 10.1097/00001622-200011000-00013.
6
[New strategies to overcome imatinib resistance in treatment for chronic myelocytic leukemia].[克服慢性粒细胞白血病治疗中伊马替尼耐药的新策略]
Zhonghua Zhong Liu Za Zhi. 2006 Aug;28(8):561-3.
7
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.一种用于慢性粒细胞白血病的Bcr/Abl激酶拮抗剂：一条充满希望的进展之路浮现出来。
J Natl Cancer Inst. 1999 Jan 20;91(2):102-3. doi: 10.1093/jnci/91.2.102.
8
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.STI571：一种用于治疗慢性粒细胞白血病的BCR-ABL酪氨酸激酶抑制剂。
Lancet Oncol. 2000 Dec;1:207-11. doi: 10.1016/s1470-2045(00)00149-2.
9
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.用于慢性粒细胞白血病的BCR-ABL酪氨酸激酶抑制剂
N Engl J Med. 2007 Jul 19;357(3):258-65. doi: 10.1056/NEJMct071828.
10
AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells.AKT诱导的活性氧产生源自慢性髓性白血病祖细胞的伊马替尼耐药克隆。
Leukemia. 2014 Dec;28(12):2416-8. doi: 10.1038/leu.2014.249. Epub 2014 Aug 25.
引用本文的文献
1
Impact of non-coding RNAs on resistance to imatinib in chronic myelogenous leukemia.非编码RNA对慢性粒细胞白血病伊马替尼耐药性的影响。
Leuk Res Rep. 2025 Jul 10;24:100529. doi: 10.1016/j.lrr.2025.100529. eCollection 2025.
2
Serum Estrogen and its Soluble Receptor Levels in Egyptian Patients with Chronic Myeloid Leukemia: A Case-Control Study.埃及慢性髓性白血病患者血清雌激素及其可溶性受体水平：一项病例对照研究。
Indian J Hematol Blood Transfus. 2022 Apr;38(2):246-254. doi: 10.1007/s12288-021-01451-8. Epub 2021 May 23.
3
MiR-29b/Sp1/FUT4 axis modulates the malignancy of leukemia stem cells by regulating fucosylation via Wnt/β-catenin pathway in acute myeloid leukemia.miR-29b/Sp1/FUT4 轴通过 Wnt/β-catenin 通路调节岩藻糖基化来调节急性髓系白血病中白血病干细胞的恶性程度。
J Exp Clin Cancer Res. 2019 May 16;38(1):200. doi: 10.1186/s13046-019-1179-y.
4
The IGF2/IGF1R/Nanog Signaling Pathway Regulates the Proliferation of Acute Myeloid Leukemia Stem Cells.胰岛素样生长因子2/胰岛素样生长因子1受体/ Nanog信号通路调控急性髓系白血病干细胞的增殖。
Front Pharmacol. 2018 Jun 29;9:687. doi: 10.3389/fphar.2018.00687. eCollection 2018.
5
Present results and future perspectives in optimizing chronic myeloid leukemia therapy.慢性髓性白血病治疗优化的当前成果与未来展望。
Haematologica. 2018 Jun;103(6):928-930. doi: 10.3324/haematol.2017.182022.
6
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia.用于BCR-ABL1基因沉默的金纳米颗粒：提高酪氨酸激酶抑制剂在慢性髓性白血病中的疗效
Mol Ther Nucleic Acids. 2017 Jun 16;7:408-416. doi: 10.1016/j.omtn.2017.05.003. Epub 2017 May 8.
7
Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights.人类白血病的斑马鱼模型：技术进展与机制洞察
Adv Exp Med Biol. 2016;916:335-69. doi: 10.1007/978-3-319-30654-4_15.
8
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report.达沙替尼作为慢性髓性白血病急变期合并中枢神经系统受累的挽救治疗：一例报告。
Oncol Lett. 2015 Apr;9(4):1957-1961. doi: 10.3892/ol.2015.2928. Epub 2015 Feb 3.
9
Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort.口服治疗新时代慢性髓性白血病患者生存的决定因素：来自英国基于人群的患者队列的研究结果
BMJ Open. 2014 Jan 15;4(1):e004266. doi: 10.1136/bmjopen-2013-004266.
本文引用的文献
1
Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.针对细胞内 WT1 癌基因产物的治疗性人抗体。
Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.
2
Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia.初诊慢性髓系白血病的多种疗法选择。
Hematology Am Soc Hematol Educ Program. 2012;2012:115-21. doi: 10.1182/asheducation-2012.1.115.
3
Ponatinib for chronic myeloid leukemia.波纳替尼用于治疗慢性髓性白血病。
N Engl J Med. 2012 Nov 29;367(22):2148-9. doi: 10.1056/NEJMe1210796.
4
Ponatinib in refractory Philadelphia chromosome-positive leukemias.波纳替尼治疗难治性费城染色体阳性白血病。
N Engl J Med. 2012 Nov 29;367(22):2075-88. doi: 10.1056/NEJMoa1205127.
5
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.尼洛替尼治疗费城染色体阳性慢性期慢性髓性白血病的伊马替尼耐药或不耐受患者，3 个月时的初始分子反应可预测 24 个月时的反应和无事件生存。
J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29.
6
Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure.慢性髓性白血病的当前问题：监测、耐药性和功能性治愈。
J Natl Compr Canc Netw. 2012 Oct 1;10 Suppl 3:S1-S13. doi: 10.6004/jnccn.2012.0184.
7
Pushing the limits of targeted therapy in chronic myeloid leukaemia.慢性髓性白血病靶向治疗的极限探索。
Nat Rev Cancer. 2012 Jul 24;12(8):513-26. doi: 10.1038/nrc3317.
8
Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy.克拉霉素通过抑制晚期自噬增强达沙替尼诱导的慢性髓性白血病细胞死亡。
Leuk Lymphoma. 2013 Jan;54(1):198-201. doi: 10.3109/10428194.2012.698737. Epub 2012 Jul 9.
9
Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.一线达沙替尼治疗慢性髓性白血病患者早期分子反应的预测价值。
Blood. 2012 Jul 12;120(2):291-4. doi: 10.1182/blood-2012-01-407486. Epub 2012 May 29.
10
Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).慢性髓性白血病（CML）中早期的分子和细胞遗传学应答可预测长期无进展生存和总生存。
Leukemia. 2012 Sep;26(9):2096-102. doi: 10.1038/leu.2012.85. Epub 2012 Mar 26.
Zotero 插件